Drug Trial Radar · NCT02292537
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)
Last checked: Nov 20, 2026Latest source record: Feb 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
Nov 24, 2014
Primary completion
Feb 20, 2017
Study completion Feb 20, 2017
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Nov 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally to participants with later-onset Spinal Muscular Atrophy (SMA). The secondary objective is to examine the safety and tolerability of nusinersen administered intrathecally to participants with later-onset SMA.
Conditions
- Spinal Muscular Atrophy
Interventions
NusinersenDrug
Administered by intrathecal (IT) lumbar puncture (LP) injection
Sham procedureProcedure
Small needle prick on the lower back at the location where the IT injection is normally made
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) Score at Month 15Time frame: Baseline and Month 15
Locations
24 sites in 10 countries. Site status is shown where the registry gives one.
UCLA Clinical and Translational Research Center
Los Angeles, California
Lucile Packard Children's Hospital at Stanford
Palo Alto, California
Children's Hospital Colorado
Aurora, Colorado
Nemours Children's Hospital
Orlando, Florida
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Boston Children's Hospital
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Columbia University Medical Center
New York, New York
Oregon Health & Science University
Portland, Oregon
Children's Hospital of Philadelphia - Neurology
Philadelphia, Pennsylvania
Children's Medical Center
Dallas, Texas
Children's Hospital - London Health Sciences Centre
London, Ontario, Canada
McGill University Health Centre-Glen Site-CIM
Montreal, Quebec, Canada
Armand Trousseau Hospital, I-Motion, Clinical Trials Platform
Paris, France
Universitatsklinikum Essen
Essen, Germany
University Hospital Freiberg, Center for Paediatrics and Adolescent Medicine, Department of Neuropaediatrics and Muscular Disease
Freiburg im Breisgau, Germany
The University of Hong Kong, Queen Mary Hospital, Department of Paediatrics and Adolescent Medicine
Hong Kong, Hong Kong SAR, Hong Kong
AOU Policlinico G. Martino Dipartimento di Neuroscienze e Centro Clinico Nemo Sud
Messina, Italy
Fondazione Policlinico Universitario Agostino Gemelli-Universita Cattolica de Sacro Cuore-UOC Neuropsichiatre Infantile
Rome, Italy
Hyogo College of Medicine
Nishinomya-shi, Hyōgo, Japan
Tokyo Women's Medical University
Shinjuku-ku, Tokyo, Japan
Seoul National University Children's Hospital
Seoul, Korea, South Korea
Hospital Sant Joan de Deu
Barcelona, Spain
University of Gothenburg, The Queen Silvia Children's Hospital
Gothenburg, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.